DexCom, Inc. (DXCM) Total Return CAGR:-9.71%(TTM)
The total return cagr for DexCom, Inc. (DXCM) is -9.71% over the latest trailing 12-month period. The comparable SPY value is +22.75%. Year-to-date total return is +12.91%. Total return includes price appreciation and reinvested dividends.
The total return CAGR for DexCom, Inc. (DXCM) stock is -9.71% over the past 12 months. The 3 year CAGR is -15.50% and the 5 year CAGR is -5.62%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of DexCom, Inc.'s investment performance.
DXCM Total Return CAGR Chart
DexCom, Inc. (DXCM)
DXCM Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
DXCM Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 2257.48 | 2548.98 | +291.50 | +12.91% | +12.91% |
| 2025 | 2645.24 | 2257.48 | -387.76 | -14.66% | -14.66% |
| 2024 | 4220.75 | 2645.24 | -1575.51 | -37.33% | -37.33% |
| 2023 | 3851.70 | 4220.75 | +369.05 | +9.58% | +9.58% |
| 2022 | 4565.99 | 3851.70 | -714.29 | -15.64% | -15.64% |
| 2021 | 3143.88 | 4565.99 | +1422.11 | +45.23% | +45.23% |
| 2020 | 1860.20 | 3143.88 | +1283.67 | +69.01% | +69.01% |
| 2019 | 1018.71 | 1860.20 | +841.50 | +82.60% | +82.60% |
| 2018 | 488.10 | 1018.71 | +530.61 | +108.71% | +108.71% |
| 2017 | 507.82 | 488.10 | -19.73 | -3.88% | -3.88% |
| 2016 | 696.60 | 507.82 | -188.78 | -27.10% | -27.10% |
| 2015 | 468.03 | 696.60 | +228.57 | +48.84% | +48.84% |
| 2014 | 301.02 | 468.03 | +167.01 | +55.48% | +55.48% |
| 2013 | 115.65 | 301.02 | +185.37 | +160.29% | +160.29% |
| 2012 | 79.25 | 115.65 | +36.39 | +45.92% | +45.92% |
| 2011 | 115.99 | 79.25 | -36.73 | -31.67% | -31.67% |
| 2010 | 68.71 | 115.99 | +47.28 | +68.81% | +68.81% |
| 2009 | 23.47 | 68.71 | +45.24 | +192.75% | +192.75% |
| 2008 | 75.17 | 23.47 | -51.70 | -68.78% | -68.78% |
| 2007 | 84.01 | 75.17 | -8.84 | -10.53% | -10.53% |
| 2006 | 126.87 | 84.01 | -42.86 | -33.78% | -33.78% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 2,549 | +12.5% | -11.9% |
| Q1 2026 | 2,265 | -1.2% | -2.5% |
| Q4 2025 | 2,293 | +0.2% | -13.3% |
| Q3 2025 | 2,289 | -20.9% | -0.4% |
| Q2 2025 | 2,893 | +24.5% | -23.1% |
| Q1 2025 | 2,323 | -12.2% | -51.0% |
| Q4 2024 | 2,645 | +15.2% | -37.3% |
| Q3 2024 | 2,297 | -38.9% | -23.8% |
| Q2 2024 | 3,761 | -20.7% | -14.0% |
| Q1 2024 | 4,744 | +12.4% | +20.2% |
| Q4 2023 | 4,221 | +40.0% | +13.0% |
| Q3 2023 | 3,014 | -31.0% | +9.9% |
| Q2 2023 | 4,371 | +10.7% | +70.3% |
| Q1 2023 | 3,948 | +5.7% | -0.9% |
| Q4 2022 | 3,734 | +36.1% | -17.1% |
| Q3 2022 | 2,744 | +6.9% | -43.7% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach